You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMidazolam
Accession NumberDB00683  (APRD00680)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. [PubChem] Midazolam is a schedule IV drug in the United States.
Structure
Thumb
Synonyms
Buccolam
Dormicum
Midazolam
Midazolamum
External Identifiers
  • Dea No. 2884
  • Ro 21-3981/001
  • Ro 21-3981/003
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BuccolamOromucosal solution2.5 mgOromucosal useShire Services Bvba2011-09-05Not applicableEu
BuccolamOromucosal solution5 mgOromucosal useShire Services Bvba2011-09-05Not applicableEu
BuccolamOromucosal solution7.5 mgOromucosal useShire Services Bvba2011-09-05Not applicableEu
BuccolamOromucosal solution10 mgOromucosal useShire Services Bvba2011-09-05Not applicableEu
Midazolam Injectionsolution1 mgintramuscular; intravenousPfizer Canada Inc2015-03-31Not applicableCanada
Midazolam Injectionsolution1 mgintramuscular; intravenousSandoz Canada Incorporated1999-07-21Not applicableCanada
Midazolam Injectionsolution1 mgintramuscular; intravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Midazolam Injectionsolution5 mgintramuscular; intravenousPfizer Canada Inc2015-03-31Not applicableCanada
Midazolam Injectionsolution5 mgintramuscular; intravenousSandoz Canada Incorporated1999-07-21Not applicableCanada
Midazolam Injectionsolution5 mgintramuscular; intravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Midazolam Injectionsolution1 mgintramuscular; intravenousNovopharm Limited2001-12-17Not applicableCanada
Midazolam Injectionliquid5 mgintramuscular; intravenousFresenius Kabi Canada Ltd2001-03-26Not applicableCanada
Midazolam Injectionsolution5 mgintramuscular; intravenousNovopharm Limited2001-12-17Not applicableCanada
Midazolam Injectionsolution1 mgintramuscular; intravenousFresenius Kabi Canada Ltd2001-03-26Not applicableCanada
Midazolam Injection BPsolution1 mgintramuscular; intravenousHospira Healthcare CorporationNot applicableNot applicableCanada
Midazolam Injection BPsolution5 mgintramuscular; intravenousHospira Healthcare CorporationNot applicableNot applicableCanada
Midazolam Injection Sdzsolution1 mgintramuscular; intravenousSandoz Canada Incorporated2012-07-26Not applicableCanada
Midazolam Injection Sdzsolution5 mgintramuscular; intravenousSandoz Canada Incorporated2012-07-26Not applicableCanada
Midazolam Injection USPsolution1 mgintramuscular; intravenousHospira Healthcare Corporation2015-03-30Not applicableCanada
Midazolam Injection USPsolution5 mgintramuscular; intravenousHospira Healthcare Corporation2016-02-09Not applicableCanada
Midazolam Injection USPsolution5 mgintramuscular; intravenousHospira Healthcare Corporation2016-02-16Not applicableCanada
Midazolam Injection USPsolution1 mgintramuscular; intravenousHospira Healthcare Corporation2016-06-15Not applicableCanada
PMS-midazolamliquid1 mgintramuscular; intravenousPharmascience IncNot applicableNot applicableCanada
PMS-midazolamliquid5 mgintramuscular; intravenousPharmascience IncNot applicableNot applicableCanada
Versed Inj 1mg/mlliquid1 mgintramuscular; intravenousHoffmann La Roche Limited1989-12-312004-07-07Canada
Versed Inj 5mg/mlliquid5 mgintramuscular; intravenousHoffmann La Roche Limited1988-12-312004-06-28Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-midazolam Injectable 1 mg/mlliquid1 mgintramuscular; intravenousApotex Inc2001-04-102013-08-02Canada
Apo-midazolam Injectable 5 mg/mlliquid5 mgintramuscular; intravenousApotex Inc2001-04-102013-08-02Canada
Midazolaminjection, solution2 mg/2mLintramuscular; intravenousBD Rx Inc.2014-10-03Not applicableUs
Midazolaminjection1 mg/mLintramuscular; intravenousA S Medication Solutions Llc2000-06-20Not applicableUs
Midazolaminjection, solution1 mg/mLintramuscular; intravenousThe Medicines Company2000-07-14Not applicableUs
Midazolaminjection5 mg/mLintramuscular; intravenousAkorn, Inc.2005-05-06Not applicableUs
Midazolaminjection, solution1 mg/mLintramuscular; intravenousCardinal Health2000-07-14Not applicableUs
Midazolaminjection, solution1 mg/mLintramuscular; intravenousThe Medicines Company2000-07-10Not applicableUs
Midazolaminjection5 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2000-06-20Not applicableUs
Midazolaminjection1 mg/mLintramuscular; intravenousSagent Pharmaceuticals2012-03-19Not applicableUs
Midazolaminjection5 mg/mLintramuscular; intravenousCardinal Health2000-06-20Not applicableUs
Midazolaminjection, solution1 mg/mLintramuscular; intravenousAPP Pharmaceuticals, LLC2000-07-14Not applicableUs
Midazolaminjection, solution5 mg/mLintramuscular; intravenousBD Rx Inc.2014-10-03Not applicableUs
Midazolaminjection1 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2000-06-20Not applicableUs
Midazolaminjection1 mg/mLintramuscular; intravenousCaraco Pharmaceutical Laboratories, Ltd.2012-08-08Not applicableUs
Midazolaminjection, solution5 mg/mLintramuscular; intravenousThe Medicines Company2000-07-14Not applicableUs
Midazolaminjection, solution5 mg/mLintramuscular; intravenousThe Medicines Company2000-07-14Not applicableUs
Midazolaminjection5 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2000-06-20Not applicableUs
Midazolaminjection5 mg/mLintramuscular; intravenousSagent Pharmaceuticals2012-03-19Not applicableUs
Midazolaminjection5 mg/mLintramuscular; intravenousCardinal Health2000-06-20Not applicableUs
Midazolaminjection, solution1 mg/mLintramuscular; intravenousAPP Pharmaceuticals, LLC2000-07-10Not applicableUs
Midazolaminjection, solution10 mg/2mLintramuscular; intravenousBD Rx Inc.2014-10-03Not applicableUs
Midazolaminjection1 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2000-06-20Not applicableUs
Midazolaminjection, solution1 mg/mLintramuscular; intravenousSagent Pharmaceuticals2012-03-19Not applicableUs
Midazolaminjection5 mg/mLintramuscular; intravenousCaraco Pharmaceutical Laboratories, Ltd.2012-08-08Not applicableUs
Midazolaminjection, solution5 mg/mLintramuscular; intravenousThe Medicines Company2000-07-14Not applicableUs
Midazolaminjection5 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2000-06-20Not applicableUs
Midazolaminjection5 mg/mLintramuscular; intravenousA S Medication Solutions Llc2000-06-20Not applicableUs
Midazolaminjection1 mg/mLintramuscular; intravenousCardinal Health2000-06-20Not applicableUs
Midazolaminjection, solution5 mg/mLintramuscular; intravenousCardinal Health2000-07-14Not applicableUs
Midazolaminjection, solution1 mg/mLintramuscular; intravenousThe Medicines Company2000-07-14Not applicableUs
Midazolaminjection1 mg/mLintramuscular; intravenousWest Ward Pharmaceutical Corp.2000-06-20Not applicableUs
Midazolaminjection, solution5 mg/mLintramuscular; intravenousSagent Pharmaceuticals2012-03-19Not applicableUs
Midazolaminjection1 mg/mLintramuscular; intravenousCardinal Health2000-06-20Not applicableUs
Midazolaminjection1 mg/mLintramuscular; intravenousAkorn, Inc.2005-05-06Not applicableUs
Midazolaminjection, solution5 mg/mLintramuscular; intravenousThe Medicines Company2000-07-14Not applicableUs
Midazolam Hydrochloridesyrup2 mg/mLoralPaddock Laboratories, LLC2005-05-02Not applicableUs
Midazolam Hydrochlorideinjection, solution1 mg/mLintramuscular; intravenousCardinal Health2002-07-22Not applicableUs
Midazolam Hydrochlorideinjection5 mg/mLintramuscular; intravenousWockhardt USA LLC.2008-05-30Not applicableUs
Midazolam Hydrochlorideinjection5 mg/mLintramuscular; intravenousWockhardt Limited2008-11-10Not applicableUs
Midazolam Hydrochloridesyrup2 mg/mLoralRoxane Laboratories, Inc2002-04-30Not applicableUs
Midazolam Hydrochlorideinjection10 mg/2mLintramuscular; intravenousCardinal Health2000-06-21Not applicableUs
Midazolam Hydrochlorideinjection1 mg/mLintramuscular; intravenousPhysicians Total Care, Inc.2006-12-12Not applicableUs
Midazolam Hydrochlorideinjection1 mg/mLintramuscular; intravenousBaxter Healthcare Corporation2010-03-042015-12-29Us
Midazolam Hydrochloridesyrup2 mg/mLoralPrecision Dose Inc.2015-05-26Not applicableUs
Midazolam Hydrochlorideinjection, solution5 mg/mLintramuscular; intravenousHospira, Inc.2002-07-22Not applicableUs
Midazolam Hydrochlorideinjection, solution1 mg/mLintramuscular; intravenousCardinal Health2002-07-22Not applicableUs
Midazolam Hydrochlorideinjection1 mg/mLintramuscular; intravenousWockhardt USA LLC.2008-11-10Not applicableUs
Midazolam Hydrochlorideinjection5 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Midazolam Hydrochloridesyrup2 mg/mLoralAtlantic Biologicals Corps2002-07-05Not applicableUs
Midazolam Hydrochlorideinjection1 mg/mLintramuscular; intravenousCardinal Health2010-03-04Not applicableUs
Midazolam Hydrochlorideinjection, solution1 mg/mLintramuscular; intravenousHospira, Inc.2002-07-22Not applicableUs
Midazolam Hydrochlorideinjection2 mg/2mLintramuscular; intravenousCardinal Health2000-06-21Not applicableUs
Midazolam Hydrochlorideinjection1 mg/mLintramuscular; intravenousWockhardt Limited2008-05-30Not applicableUs
Midazolam Hydrochlorideinjection, solution5 mg/mLintramuscular; intravenousDispensing Solutions, Inc.2011-05-02Not applicableUs
Midazolam Hydrochlorideinjection, solution1 mg/mLintramuscular; intravenousHospira, Inc.2000-06-20Not applicableUs
Midazolam Hydrochlorideinjection, solution5 mg/mLintramuscular; intravenousA S Medication Solutions Llc2000-06-20Not applicableUs
Midazolam Hydrochlorideinjection, solution1 mg/mLintramuscular; intravenousCardinal Health2002-06-13Not applicableUs
Midazolam Hydrochlorideinjection5 mg/mLintramuscular; intravenousWockhardt USA LLC.2008-11-10Not applicableUs
Midazolam Hydrochlorideinjection1 mg/mLintramuscular; intravenousCardinal Health2010-03-04Not applicableUs
Midazolam Hydrochloridesyrup10 mg/5mLoralPrecision Dose Inc.2010-10-112016-08-31Us
Midazolam Hydrochlorideinjection, solution1 mg/mLintramuscular; intravenousHospira, Inc.2002-06-13Not applicableUs
Midazolam Hydrochlorideinjection5 mg/mLintramuscular; intravenousCardinal Health2000-06-21Not applicableUs
Midazolam Hydrochlorideinjection5 mg/mLintramuscular; intravenousWockhardt Limited2008-05-30Not applicableUs
Midazolam Hydrochlorideinjection1 mg/mLintramuscular; intravenousWockhardt USA LLC.2008-05-30Not applicableUs
Midazolam Hydrochlorideinjection, solution5 mg/mLintramuscular; intravenousDispensing Solutions, Inc.2011-05-03Not applicableUs
Midazolam Hydrochlorideinjection, solution5 mg/mLintramuscular; intravenousHospira, Inc.2000-06-20Not applicableUs
Midazolam Hydrochlorideinjection, solution1 mg/mLintramuscular; intravenousA S Medication Solutions Llc2000-06-20Not applicableUs
Midazolam Hydrochlorideinjection5 mg/mLintramuscular; intravenousBaxter Healthcare Corporation2010-03-042015-12-29Us
Midazolam Hydrochloridesyrup2 mg/mLoralRanbaxy Pharmaceuticlas Inc2002-07-05Not applicableUs
Midazolam Hydrochloridesyrup2 mg/mLoralPrecision Dose Inc.2015-05-26Not applicableUs
Midazolam Hydrochlorideinjection, solution5 mg/mLintramuscular; intravenousHospira, Inc.2002-06-13Not applicableUs
Midazolam Hydrochlorideinjection5 mg/mLintramuscular; intravenousCardinal Health2000-06-21Not applicableUs
Midazolam Hydrochlorideinjection1 mg/mLintramuscular; intravenousWockhardt Limited2008-11-10Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Midazolam HClinjection, solution.5 mg/mLintravenousCantrell Drug Company2013-01-30Not applicableUs
Midazolam HClinjection, solution1 mg/mLintravenousCantrell Drug Company2010-08-02Not applicableUs
International Brands
NameCompany
AnquilGeneral Pharma
BenzosedPharmaceutical
DalamRichmond
DamizolSpecifar
DemizolamDem Ilaç
DoricumRoche
DormicumRoche
DormidScott
DormipronChalver
DormireCristália
DormitolSquare
DormixalDemo
DormonidRoche
DrimnorthNorthia
EpistatusIFET
FlormidalGalenika
FulsedRanbaxy
Fulsed InjectionTerapia
GarenBio-Pharma
GobbizolamGobbi
HipnazolamEMS
HipnozPharos
HypnofastIncepta
HypnovelRoche
IpnovelRoche
NocturnaLafi
SetamRimsa
TalentumFisiopharma
TerapSanitas
VersedRoche
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Midazolam Hydrochloride
Thumb
  • InChI Key: PLYSCVSCYOQVRP-UHFFFAOYSA-N
  • Monoisotopic Mass: 361.054881082
  • Average Mass: 362.228
DBSALT000118
Categories
UNIIR60L0SM5BC
CAS number59467-70-8
WeightAverage: 325.767
Monoisotopic: 325.078203343
Chemical FormulaC18H13ClFN3
InChI KeyInChIKey=DDLIGBOFAVUZHB-UHFFFAOYSA-N
InChI
InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3
IUPAC Name
12-chloro-9-(2-fluorophenyl)-3-methyl-2,4,8-triazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaene
SMILES
CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as imidazo[1,5-a][1,4]benzodiazepines. These are compounds containing an imidazole ring and a 1,4-benzodiazepine ring system, both sharing one nitrogen atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct ParentImidazo[1,5-a][1,4]benzodiazepines
Alternative Parents
Substituents
  • Imidazo[1,5-a][1,4]benzodiazepine
  • Halobenzene
  • Fluorobenzene
  • Para-diazepine
  • Benzenoid
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Aryl chloride
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Ketimine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Imine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationThe midazolam injection is indicated for preoperative sedation/anziolysis/amnesia. It is also an agent for sedation/anziolysis/amnesia prior to or during diagnostic, therapeutic, or endoscopic procedures. Midazolam can also be given intravenously for induction of general anaesthesia.
PharmacodynamicsMidazolam is a short-acting benzodiazepine central nervous system (CNS) depressant. Pharmacodynamic properties of midazolam and its metabolites, which are similar to those of other benzodiazepines, include sedative, anxiolytic, amnesic and hypnotic activities. Benzodiazepine pharmacologic effects appear to result from reversible interactions with the (gamma)-amino butyric acid (GABA) benzodiazepine receptor in the CNS, the major inhibitory neurotransmitter in the central nervous system. The action of midazolam is readily reversed by the benzodiazepine receptor antagonist, flumazenil.
Mechanism of actionIt is thought that the actions of benzodiazepines such as midazolam are mediated through the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which is one of the major inhibitory neurotransmitters in the brain. Benzodiazepines increase the activity of GABA, thereby producing a calming effect, relaxing skeletal muscles, and inducing sleep. Benzodiazepines bind to the benzodiazepine site on GABA-A receptors, which potentiates the effects of GABA by increasing the frequency of chloride channel opening.
Related Articles
AbsorptionRapidly absorbed after oral administration. The absolute bioavailability of the midazolam syrup in pediatric patients is about 36%. The absolute bioavailability, if given intramuscularly (IM), is greater than 90%. Cmax, IM = 90 ng/mL; Tmax, IM = 0.5 hours. Following IM administered, Cmax for midazolam and its 1-hydroxy metabolite were approxiately one-half of those achieved after intravenous injection.
Volume of distribution
  • 1.24 to 2.02 L/kg [pediatric patients (6 months to <16 years) receiving 0.15 mg/kg IV midazolam,]
  • 1 to 3.1 L/kg [intravenously administered, healthy adults]
    Female gender, old age, and obesity may increase the volume of distribution. Midazolam may also cross the placenta and has been detected in human milk and cerebrospinal fluid.
Protein binding97% protein bound.
Metabolism

Midazolam is primarily metabolized in the liver and gut by human cytochrome P450 IIIA4 (CYP3A4) to its pharmacologic active metabolite, (alpha)-hydroxymidazolam (also known as 1-hydroxy-midazolam), and 4-hydroxymidazolam (makes up 5% or less of the biotransformation products). 1-hydroxy-midazolam is at least as potent as the parent compound and may contributed to the overall activity of midazolam. In vitro studies have demonstrated that the affinities of 1- and 4-hydroxy-midazolam for the benzodiazepine receptor are approximately 20% and 7%, respectively, relative to midazolam. It also undergoes N-glucuronidation via UGT1A4.

SubstrateEnzymesProduct
Midazolam
Alpha-hydroxymidazolamDetails
Midazolam
4-hydroxymidazolamDetails
Route of eliminationMidazolam is primarily metabolized in the liver and gut by human cytochrome P450 IIIA4 (CYP3A4) to its pharmacologic active metabolite, α-hydroxymidazolam, followed by glucuronidation of the α–hydroxyl metabolite which is present in unconjugated and conjugated forms in human plasma. The α- hydroxymidazolam glucuronide is then excreted in urine. No significant amount of parent drug or metabolites is extractable from urine before beta-glucuronidase and sulfatase deconjugation, indicating that the urinary metabolites are excreted mainly as conjugates. The amount of midazolam excreted unchanged in the urine when given intravenously is less than 0.5%. 45% to 57% of the dose was excreted in the urine as 1-hydroxymethyl midazolam conjugate.
Half lifeIntravenous, healthy adults = 1.8 to 6.4 hours (mean of 3 hours)
Clearance
  • 9.3 to 11 mL/min/kg [pediatric patients (6 months to <16 years old)]
  • 0.25 to 0.54 L/hr/kg [intravenous, healthy adults]
ToxicityLD50=825 mg/kg (Orally in rats). Signs of overdose include sedation, somnolence, confusion, impaired coordination, diminished reflexes, coma, and deleterious effects on vital signs.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9724
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.5074
P-glycoprotein inhibitor IInhibitor0.5587
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.7476
CYP450 2C9 substrateNon-substrate0.7366
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7194
CYP450 1A2 substrateInhibitor0.8586
CYP450 2C9 inhibitorInhibitor0.7132
CYP450 2D6 inhibitorNon-inhibitor0.6887
CYP450 2C19 inhibitorInhibitor0.6554
CYP450 3A4 inhibitorNon-inhibitor0.5214
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9001
Ames testNon AMES toxic0.8024
CarcinogenicityNon-carcinogens0.7703
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1488 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9827
hERG inhibition (predictor II)Non-inhibitor0.7379
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apothecon inc div bristol myers squibb
  • App pharmaceuticals llc
  • Astrazeneca pharmaceuticals lp
  • Baxter healthcare corp anesthesia and critical care
  • Baxter healthcare corp anesthesia critical care
  • Bedford laboratories div ben venue laboratories inc
  • Ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • International medicated systems ltd
  • International medication systems ltd
  • Taylor pharmaceuticals
  • Wockhardt ltd
  • Hlr technology
  • Apotex inc richmond hill
  • Hi tech pharmacal co inc
  • Paddock laboratories inc
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
  • Hoffmann la roche inc
Packagers
Dosage forms
FormRouteStrength
Liquidintramuscular; intravenous1 mg
Liquidintramuscular; intravenous5 mg
Oromucosal solutionOromucosal use10 mg
Oromucosal solutionOromucosal use2.5 mg
Oromucosal solutionOromucosal use5 mg
Oromucosal solutionOromucosal use7.5 mg
Injectionintramuscular; intravenous1 mg/mL
Injectionintramuscular; intravenous5 mg/mL
Injection, solutionintramuscular; intravenous10 mg/2mL
Injection, solutionintramuscular; intravenous2 mg/2mL
Injection, solutionintravenous.5 mg/mL
Injection, solutionintravenous1 mg/mL
Injectionintramuscular; intravenous10 mg/2mL
Injectionintramuscular; intravenous2 mg/2mL
Injection, solutionintramuscular; intravenous1 mg/mL
Injection, solutionintramuscular; intravenous5 mg/mL
Syruporal10 mg/5mL
Syruporal2 mg/mL
Solutionintramuscular; intravenous1 mg
Solutionintramuscular; intravenous5 mg
Prices
Unit descriptionCostUnit
Midazolam 5 mg/ml3.9USD ml
Midazolam-nacl 2 mg/ml inj2.31USD ml
Midazolam hcl 5 mg/ml vial1.18USD ml
Midazolam-nacl 1 mg/ml inj1.13USD ml
Midazolam hcl 2 mg/ml syrup1.08USD ml
Midazolam 1 mg/ml isecure syr0.73USD ml
Midazolam hcl 1 mg/ml vial0.26USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point159 °CPhysProp
water solubility0.024 mg/mLThorsteinn Loftsson and Dagný Hreinsdóttir, 2006
Predicted Properties
PropertyValueSource
Water Solubility0.00987 mg/mLALOGPS
logP3.89ALOGPS
logP3.33ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)6.57ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area30.18 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity99.43 m3·mol-1ChemAxon
Polarizability32.7 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-03di-3839000000-42781254e15bcd5b31b6View in MoNA
References
Synthesis Reference

Madhup K. Dhaon, “Process for the preparation of midazolam.” U.S. Patent US6262260, issued August, 1979.

US6262260
General References
  1. Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. [PubMed:6135616 ]
  2. Isojarvi JI, Tokola RA: Benzodiazepines in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res. 1998 Dec;42 Suppl 1:80-92. [PubMed:10030438 ]
  3. Garratt JC, Gent JP, Feely M, Haigh JR: Can benzodiazepines be classified by characterising their anticonvulsant tolerance-inducing potential? Eur J Pharmacol. 1988 Jan 5;145(1):75-80. [PubMed:2894998 ]
  4. Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. [PubMed:17287588 ]
  5. Vermeeren A: Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328. [PubMed:15089115 ]
External Links
ATC CodesN05CD08
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.7 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Midazolam can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Midazolam can be increased when it is combined with 3,4-Dichloroisocoumarin.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Midazolam can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Midazolam is combined with 7-Nitroindazole.
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Midazolam.
AcepromazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Midazolam.
AcetaminophenThe serum concentration of Midazolam can be increased when it is combined with Acetaminophen.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Midazolam.
adipiplonThe risk or severity of adverse effects can be increased when Midazolam is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Midazolam.
AfatinibThe serum concentration of Midazolam can be increased when it is combined with Afatinib.
AgomelatineThe risk or severity of adverse effects can be increased when Midazolam is combined with Agomelatine.
AlbendazoleThe serum concentration of Midazolam can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Midazolam can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Midazolam can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Midazolam is combined with Alfaxalone.
AlfentanilThe serum concentration of Midazolam can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Midazolam is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Midazolam.
AlogliptinThe serum concentration of Midazolam can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Midazolam can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Midazolam is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Midazolam.
AmantadineThe serum concentration of Midazolam can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Midazolam.
Aminohippuric acidThe serum concentration of Midazolam can be increased when it is combined with Aminohippuric acid.
AminophyllineThe therapeutic efficacy of Midazolam can be decreased when used in combination with Aminophylline.
AmiodaroneThe serum concentration of Midazolam can be decreased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Midazolam is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Midazolam.
AmitriptylineThe serum concentration of Midazolam can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Midazolam can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Midazolam is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Midazolam is combined with Amperozide.
AmprenavirThe serum concentration of Midazolam can be increased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Midazolam can be increased when it is combined with Amsacrine.
Antithrombin III humanThe serum concentration of Midazolam can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Midazolam can be increased when it is combined with Apixaban.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Midazolam.
AprepitantThe serum concentration of Midazolam can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Midazolam can be increased when it is combined with Aprotinin.
ArgatrobanThe serum concentration of Midazolam can be increased when it is combined with Argatroban.
AripiprazoleThe risk or severity of adverse effects can be increased when Midazolam is combined with Aripiprazole.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Midazolam.
ArticaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Midazolam is combined with Asenapine.
AstemizoleThe serum concentration of Midazolam can be increased when it is combined with Astemizole.
AsunaprevirThe serum concentration of Midazolam can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Midazolam can be increased when it is combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Midazolam.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Midazolam.
AtenololThe serum concentration of Midazolam can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Midazolam can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Midazolam can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Midazolam.
AzaperoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Azaperone.
AzelastineMidazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Midazolam can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Midazolam can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Midazolam is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Barbital.
BatimastatThe serum concentration of Midazolam can be increased when it is combined with Batimastat.
BenazeprilThe serum concentration of Midazolam can be increased when it is combined with Benazepril.
BenzamidineThe serum concentration of Midazolam can be increased when it is combined with Benzamidine.
BenzocaineThe serum concentration of Midazolam can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Midazolam is combined with Benzyl alcohol.
BepridilThe serum concentration of Midazolam can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Midazolam.
BexaroteneThe serum concentration of Midazolam can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Midazolam can be increased when it is combined with Biperiden.
BivalirudinThe serum concentration of Midazolam can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Midazolam can be increased when it is combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Midazolam.
BortezomibThe metabolism of Midazolam can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Midazolam can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Midazolam.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Midazolam.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Midazolam is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.
BrimonidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Bromazepam.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Midazolam.
BromocriptineThe serum concentration of Midazolam can be increased when it is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Midazolam is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Midazolam.
BuprenorphineThe serum concentration of Midazolam can be increased when it is combined with Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Buprenorphine.
BuspironeThe serum concentration of Midazolam can be increased when it is combined with Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Midazolam is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Midazolam.
ButacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Midazolam is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Midazolam is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Midazolam.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Midazolam.
CabazitaxelThe serum concentration of Midazolam can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Midazolam.
CaffeineThe serum concentration of Midazolam can be increased when it is combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Midazolam.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Midazolam.
CanagliflozinThe serum concentration of Midazolam can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Midazolam can be increased when it is combined with Candesartan.
CandoxatrilThe serum concentration of Midazolam can be increased when it is combined with Candoxatril.
CaptoprilThe serum concentration of Midazolam can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Midazolam can be decreased when it is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Midazolam is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Midazolam.
CarisoprodolThe risk or severity of adverse effects can be increased when Midazolam is combined with Carisoprodol.
CarvedilolThe serum concentration of Midazolam can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Midazolam can be increased when it is combined with Caspofungin.
CeritinibThe serum concentration of Midazolam can be increased when it is combined with Ceritinib.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Midazolam.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Midazolam.
CetirizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Midazolam is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Midazolam.
ChlormezanoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Chloroprocaine.
ChloroquineThe serum concentration of Midazolam can be increased when it is combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlorphenamine.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Midazolam.
ChlorpromazineThe serum concentration of Midazolam can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Midazolam can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Midazolam can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Chlorzoxazone.
CholesterolThe serum concentration of Midazolam can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Midazolam can be decreased when it is combined with Cholic Acid.
ChymostatinThe serum concentration of Midazolam can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Midazolam can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Midazolam can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Midazolam can be decreased when it is combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Midazolam.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Midazolam.
CiprofloxacinThe serum concentration of Midazolam can be increased when it is combined with Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Midazolam.
CitalopramThe risk or severity of adverse effects can be increased when Midazolam is combined with Citalopram.
CitalopramThe serum concentration of Midazolam can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Midazolam.
ClarithromycinThe serum concentration of Midazolam can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Midazolam can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Midazolam is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Midazolam is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Midazolam.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Midazolam.
ClofazimineThe serum concentration of Midazolam can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when Midazolam is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Midazolam.
ClomipramineThe risk or severity of adverse effects can be increased when Midazolam is combined with Clomipramine.
ClomipramineThe serum concentration of Midazolam can be increased when it is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Midazolam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Midazolam.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Midazolam.
ClopidogrelThe metabolism of Midazolam can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Midazolam.
ClotrimazoleThe metabolism of Midazolam can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Midazolam.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Midazolam.
CobicistatThe serum concentration of Midazolam can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Midazolam.
CocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Midazolam.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Midazolam.
ColchicineThe serum concentration of Midazolam can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Midazolam can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Midazolam can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Midazolam.
CrizotinibThe metabolism of Midazolam can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Midazolam.
CyclizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyclobenzaprine.
CyclophosphamideThe serum concentration of Midazolam can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Midazolam can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Midazolam.
CyproheptadineThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyproheptadine.
Dabigatran etexilateThe serum concentration of Midazolam can be increased when it is combined with Dabigatran etexilate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Midazolam.
DabrafenibThe serum concentration of Midazolam can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Midazolam can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Midazolam.
DactinomycinThe serum concentration of Midazolam can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Midazolam is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Midazolam.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Midazolam.
DapoxetineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dapoxetine.
DarunavirThe serum concentration of Midazolam can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Midazolam can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Midazolam.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Midazolam.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Midazolam.
DeferasiroxThe serum concentration of Midazolam can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Midazolam can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Midazolam is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Midazolam is combined with Desflurane.
DesipramineThe serum concentration of Midazolam can be increased when it is combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Midazolam is combined with Desipramine.
DesloratadineThe serum concentration of Midazolam can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Midazolam is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Detomidine.
DexamethasoneThe serum concentration of Midazolam can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Midazolam.
DextromethorphanThe serum concentration of Midazolam can be increased when it is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Midazolam is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Midazolam.
DezocineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Midazolam.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Midazolam.
DiclofenacThe serum concentration of Midazolam can be increased when it is combined with Diclofenac.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Midazolam.
DifenoxinThe risk or severity of adverse effects can be increased when Midazolam is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Midazolam.
DigoxinThe serum concentration of Midazolam can be decreased when it is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Midazolam can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Midazolam.
DiltiazemThe metabolism of Midazolam can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Midazolam.
DimenhydrinateThe risk or severity of adverse effects can be increased when Midazolam is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Midazolam is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Midazolam is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Midazolam.
DipyridamoleThe serum concentration of Midazolam can be increased when it is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Midazolam.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Midazolam.
DoramectinThe risk or severity of adverse effects can be increased when Midazolam is combined with Doramectin.
DoxazosinThe serum concentration of Midazolam can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Midazolam can be increased when it is combined with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Midazolam is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Midazolam.
DoxycyclineThe metabolism of Midazolam can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.
DoxylamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Midazolam is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Midazolam.
DronedaroneThe metabolism of Midazolam can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Midazolam.
DrotebanolThe risk or severity of adverse effects can be increased when Midazolam is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Midazolam.
DyphyllineThe therapeutic efficacy of Midazolam can be decreased when used in combination with Dyphylline.
EcabetThe serum concentration of Midazolam can be increased when it is combined with Ecabet.
EcgonineThe risk or severity of adverse effects can be increased when Midazolam is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Midazolam is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Midazolam can be increased when it is combined with Edoxaban.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Midazolam.
EfavirenzThe serum concentration of Midazolam can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Midazolam is combined with Efavirenz.
ElafinThe serum concentration of Midazolam can be increased when it is combined with Elafin.
ElbasvirThe serum concentration of Midazolam can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Midazolam.
EnalaprilThe serum concentration of Midazolam can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Midazolam can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Midazolam can be increased when it is combined with Enalkiren.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Midazolam.
EntacaponeThe risk or severity of adverse effects can be increased when Midazolam is combined with Entacapone.
EnzalutamideThe serum concentration of Midazolam can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Midazolam.
ErgonovineThe serum concentration of Midazolam can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Midazolam can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Midazolam.
ErythromycinThe metabolism of Midazolam can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Midazolam.
EscitalopramThe risk or severity of adverse effects can be increased when Midazolam is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Midazolam can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Midazolam.
EstramustineThe serum concentration of Midazolam can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Midazolam.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Midazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Midazolam.
EthanolMidazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Midazolam.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Midazolam.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Midazolam.
EthosuximideThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Midazolam is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Midazolam.
EtoperidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Midazolam.
EtoposideThe serum concentration of Midazolam can be increased when it is combined with Etoposide.
EtorphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Etorphine.
EtravirineThe serum concentration of Midazolam can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Midazolam.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Midazolam.
EzogabineThe risk or severity of adverse effects can be increased when Midazolam is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Midazolam is combined with Felbamate.
FelodipineThe serum concentration of Midazolam can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Midazolam is combined with Fenfluramine.
FentanylThe serum concentration of Midazolam can be increased when it is combined with Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Midazolam is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Midazolam.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Midazolam.
FexofenadineThe serum concentration of Midazolam can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Midazolam.
FidaxomicinThe serum concentration of Midazolam can be increased when it is combined with Fidaxomicin.
FlibanserinThe risk or severity of adverse effects can be increased when Midazolam is combined with Flibanserin.
FluconazoleThe metabolism of Midazolam can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluoxetine.
FluoxetineThe serum concentration of Midazolam can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Midazolam can be increased when it is combined with Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Midazolam is combined with Flupentixol.
FluphenazineThe serum concentration of Midazolam can be increased when it is combined with Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluphenazine.
FlurazepamThe serum concentration of Midazolam can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Midazolam.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Fluvoxamine.
FluvoxamineThe metabolism of Midazolam can be decreased when combined with Fluvoxamine.
FosamprenavirThe serum concentration of Midazolam can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Midazolam can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Midazolam can be increased when it is combined with Fosinopril.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Midazolam.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Midazolam.
FospropofolThe risk or severity of adverse effects can be increased when Midazolam is combined with Fospropofol.
Fusidic AcidThe serum concentration of Midazolam can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Midazolam is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Midazolam is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Midazolam is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Midazolam.
GefitinibThe serum concentration of Midazolam can be increased when it is combined with Gefitinib.
GeldanamycinThe serum concentration of Midazolam can be increased when it is combined with Geldanamycin.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Midazolam.
GenisteinThe serum concentration of Midazolam can be increased when it is combined with Genistein.
Ginkgo bilobaThe serum concentration of Midazolam can be decreased when it is combined with Ginkgo biloba.
GlutethimideThe risk or severity of adverse effects can be increased when Midazolam is combined with Glutethimide.
GlyburideThe serum concentration of Midazolam can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Midazolam can be increased when it is combined with Glycerol.
GM6001The serum concentration of Midazolam can be increased when it is combined with GM6001.
Gramicidin DThe serum concentration of Midazolam can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Midazolam.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Midazolam.
GrepafloxacinThe serum concentration of Midazolam can be increased when it is combined with Grepafloxacin.
GuanfacineThe risk or severity of adverse effects can be increased when Midazolam is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Halazepam.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Midazolam.
HaloperidolThe serum concentration of Midazolam can be increased when it is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Midazolam is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Midazolam is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Hexobarbital.
HirulogThe serum concentration of Midazolam can be increased when it is combined with Hirulog.
HydrocodoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Midazolam.
HydrocortisoneThe serum concentration of Midazolam can be increased when it is combined with Hydrocortisone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Midazolam.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.
HydroxyzineThe risk or severity of adverse effects can be increased when Midazolam is combined with Hydroxyzine.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Midazolam.
IdelalisibThe serum concentration of Midazolam can be increased when it is combined with Idelalisib.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Midazolam.
IloperidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Iloperidone.
ImatinibThe metabolism of Midazolam can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Midazolam.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Midazolam.
ImipramineThe serum concentration of Midazolam can be increased when it is combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Midazolam.
IndalpineThe risk or severity of adverse effects can be increased when Midazolam is combined with Indalpine.
IndinavirThe serum concentration of Midazolam can be increased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Midazolam.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Midazolam.
IndomethacinThe serum concentration of Midazolam can be increased when it is combined with Indomethacin.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Midazolam.
IsavuconazoniumThe metabolism of Midazolam can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Midazolam is combined with Isoflurane.
IsoflurophateThe serum concentration of Midazolam can be increased when it is combined with Isoflurophate.
IsradipineThe metabolism of Midazolam can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Midazolam can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Midazolam can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Midazolam.
IvermectinThe serum concentration of Midazolam can be increased when it is combined with Ivermectin.
IxazomibThe serum concentration of Midazolam can be increased when it is combined with Ixazomib.
KetamineThe serum concentration of Midazolam can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Midazolam.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Midazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Ketobemidone.
KetoconazoleThe serum concentration of Midazolam can be increased when it is combined with Ketoconazole.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Midazolam.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Midazolam.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Midazolam.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Midazolam.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Midazolam.
LansoprazoleThe serum concentration of Midazolam can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Midazolam can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Midazolam.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Midazolam.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Midazolam.
LepirudinThe serum concentration of Midazolam can be increased when it is combined with Lepirudin.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Midazolam.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Midazolam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Midazolam is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Midazolam is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Midazolam.
LevofloxacinThe serum concentration of Midazolam can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Midazolam is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Midazolam is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Midazolam is combined with Levorphanol.
LevothyroxineThe serum concentration of Midazolam can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Midazolam can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Lidocaine.
LinagliptinThe serum concentration of Midazolam can be increased when it is combined with Linagliptin.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Midazolam.
LiothyronineThe serum concentration of Midazolam can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Midazolam can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Midazolam can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Midazolam is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Midazolam is combined with Lofentanil.
LomitapideThe serum concentration of Midazolam can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Midazolam.
LoperamideThe serum concentration of Midazolam can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Midazolam can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Midazolam can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Midazolam is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Midazolam.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Midazolam.
LosartanThe serum concentration of Midazolam can be increased when it is combined with Losartan.
LovastatinThe metabolism of Midazolam can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Midazolam.
Lu AA21004The risk or severity of adverse effects can be increased when Midazolam is combined with Lu AA21004.
LuliconazoleThe serum concentration of Midazolam can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Midazolam can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Midazolam.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Midazolam is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Midazolam.
MaprotilineThe serum concentration of Midazolam can be increased when it is combined with Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Midazolam is combined with Maprotiline.
MebendazoleThe serum concentration of Midazolam can be increased when it is combined with Mebendazole.
MeclizineThe risk or severity of adverse effects can be increased when Midazolam is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Medetomidine.
MefloquineThe serum concentration of Midazolam can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Midazolam can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Midazolam is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Mepivacaine.
MeprobamateThe serum concentration of Midazolam can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Midazolam is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Midazolam is combined with Metaxalone.
MethadoneMidazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethadoneThe serum concentration of Midazolam can be increased when it is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Midazolam is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Midazolam is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Midazolam is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Midazolam.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Midazolam.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Midazolam is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Midazolam is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Midazolam is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Midazolam.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Midazolam.
MetoprololThe serum concentration of Midazolam can be increased when it is combined with Metoprolol.
MetyrosineMidazolam may increase the sedative activities of Metyrosine.
MibefradilThe serum concentration of Midazolam can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Midazolam can be increased when it is combined with Miconazole.
MifepristoneThe metabolism of Midazolam can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Midazolam is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Midazolam.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Midazolam.
MirtazapineMidazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Midazolam.
MitomycinThe serum concentration of Midazolam can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Midazolam can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Midazolam.
ModafinilThe serum concentration of Midazolam can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Midazolam can be increased when it is combined with Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Molindone.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Midazolam.
MorphineThe serum concentration of Midazolam can be increased when it is combined with Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Midazolam.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Midazolam can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Midazolam.
NabiloneThe risk or severity of adverse effects can be increased when Midazolam is combined with Nabilone.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Midazolam.
NafcillinThe serum concentration of Midazolam can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Midazolam is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Midazolam.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Midazolam.
NaltrexoneThe serum concentration of Midazolam can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Midazolam can be increased when it is combined with Naringenin.
NCX 4016The serum concentration of Midazolam can be increased when it is combined with NCX 4016.
NefazodoneThe serum concentration of Midazolam can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Midazolam can be increased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Midazolam.
NeostigmineThe serum concentration of Midazolam can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Midazolam can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Midazolam can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Midazolam.
NicardipineThe serum concentration of Midazolam can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Midazolam can be decreased when it is combined with Nifedipine.
NilotinibThe metabolism of Midazolam can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Midazolam.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Midazolam.
NisoldipineThe serum concentration of Midazolam can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Midazolam can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Nitrazepam.
NitrendipineThe serum concentration of Midazolam can be increased when it is combined with Nitrendipine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Midazolam is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Midazolam.
NorethisteroneThe serum concentration of Midazolam can be decreased when it is combined with Norethisterone.
NormethadoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Midazolam is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Midazolam.
OlaparibThe metabolism of Midazolam can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Midazolam is combined with Olopatadine.
OmapatrilatThe serum concentration of Midazolam can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Midazolam.
OmeprazoleThe serum concentration of Midazolam can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Midazolam is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Midazolam is combined with Opium.
OrphenadrineMidazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Midazolam.
OsanetantThe risk or severity of adverse effects can be increased when Midazolam is combined with Osanetant.
OsimertinibThe serum concentration of Midazolam can be increased when it is combined with Osimertinib.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Midazolam.
OtamixabanThe serum concentration of Midazolam can be increased when it is combined with Otamixaban.
OxazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Midazolam.
OxymorphoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxymorphone.
P-NitrophenolThe serum concentration of Midazolam can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Midazolam.
PaclitaxelThe serum concentration of Midazolam can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Midazolam can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Paliperidone.
Palmitic AcidThe serum concentration of Midazolam can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Midazolam.
PantoprazoleThe serum concentration of Midazolam can be increased when it is combined with Pantoprazole.
ParaldehydeMidazolam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Midazolam.
ParoxetineThe risk or severity of adverse effects can be increased when Midazolam is combined with Paroxetine.
ParoxetineThe serum concentration of Midazolam can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Midazolam.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Midazolam.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Midazolam.
PerampanelThe risk or severity of adverse effects can be increased when Midazolam is combined with Perampanel.
PerindoprilThe serum concentration of Midazolam can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Midazolam is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Midazolam.
PhenobarbitalThe serum concentration of Midazolam can be decreased when it is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Midazolam is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Midazolam.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Midazolam.
PhosphoramidonThe serum concentration of Midazolam can be increased when it is combined with Phosphoramidon.
PimozideThe serum concentration of Midazolam can be increased when it is combined with Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Midazolam is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Pipotiazine.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Midazolam.
PizotifenThe risk or severity of adverse effects can be increased when Midazolam is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Midazolam can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Midazolam.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Midazolam.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Midazolam.
PonatinibThe serum concentration of Midazolam can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Midazolam can be increased when it is combined with Posaconazole.
PramipexoleMidazolam may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Midazolam.
PravastatinThe serum concentration of Midazolam can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Midazolam.
PrazosinThe serum concentration of Midazolam can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Midazolam.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Midazolam.
PrednisoneThe serum concentration of Midazolam can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Midazolam.
PrilocaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Primidone.
PrinomastatThe serum concentration of Midazolam can be increased when it is combined with Prinomastat.
ProbenecidThe serum concentration of Midazolam can be increased when it is combined with Probenecid.
ProcaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Midazolam.
ProgesteroneThe serum concentration of Midazolam can be decreased when it is combined with Progesterone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Midazolam.
PromethazineThe serum concentration of Midazolam can be increased when it is combined with Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Promethazine.
PropafenoneThe serum concentration of Midazolam can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Proparacaine.
PropofolThe serum concentration of Propofol can be increased when it is combined with Midazolam.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Midazolam.
PropoxycaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Midazolam.
PropranololThe serum concentration of Midazolam can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Midazolam can be increased when it is combined with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Midazolam is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Midazolam.
PSD502The risk or severity of adverse effects can be increased when Midazolam is combined with PSD502.
QuazepamThe serum concentration of Midazolam can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Quazepam.
QuercetinThe serum concentration of Midazolam can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Midazolam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Midazolam.
QuinacrineThe serum concentration of Midazolam can be increased when it is combined with Quinacrine.
QuinaprilThe serum concentration of Midazolam can be increased when it is combined with Quinapril.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Midazolam.
QuinidineThe serum concentration of Midazolam can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Midazolam.
QuinineThe serum concentration of Midazolam can be increased when it is combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Midazolam is combined with Ramelteon.
RamiprilThe serum concentration of Midazolam can be increased when it is combined with Ramipril.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Midazolam.
RanitidineThe serum concentration of Midazolam can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Midazolam.
ReboxetineThe serum concentration of Midazolam can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Midazolam can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Midazolam is combined with Remifentanil.
RemikirenThe serum concentration of Midazolam can be increased when it is combined with Remikiren.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Midazolam.
ReserpineThe serum concentration of Midazolam can be decreased when it is combined with Reserpine.
RifabutinThe metabolism of Midazolam can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Midazolam can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Midazolam can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Midazolam.
RilpivirineThe serum concentration of Midazolam can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Midazolam.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Midazolam.
RitonavirThe serum concentration of Midazolam can be increased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Midazolam.
RivaroxabanThe serum concentration of Midazolam can be increased when it is combined with Rivaroxaban.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Midazolam.
RolapitantThe serum concentration of Midazolam can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Midazolam.
RomifidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Romifidine.
RopiniroleMidazolam may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Midazolam.
RotigotineMidazolam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Midazolam.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Midazolam is combined with S-Ethylisothiourea.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Midazolam.
SaquinavirThe serum concentration of Midazolam can be increased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Midazolam.
SaxagliptinThe serum concentration of Midazolam can be increased when it is combined with Saxagliptin.
ScopolamineThe serum concentration of Midazolam can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Midazolam.
SelegilineThe serum concentration of Midazolam can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Midazolam.
SertindoleThe risk or severity of adverse effects can be increased when Midazolam is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Midazolam is combined with Sertraline.
SertralineThe serum concentration of Midazolam can be increased when it is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Midazolam is combined with Sevoflurane.
SildenafilThe metabolism of Midazolam can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Midazolam.
SiltuximabThe serum concentration of Midazolam can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Midazolam can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Midazolam.
SimvastatinThe serum concentration of Midazolam can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Midazolam can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Midazolam can be increased when it is combined with Sitagliptin.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Midazolam.
Sodium oxybateMidazolam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Midazolam.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Midazolam.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Midazolam.
SorafenibThe serum concentration of Midazolam can be increased when it is combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Midazolam.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Midazolam.
SpiraprilThe serum concentration of Midazolam can be increased when it is combined with Spirapril.
SpironolactoneThe serum concentration of Midazolam can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Midazolam can be decreased when it is combined with St. John&#39;s Wort.
StaurosporineThe serum concentration of Midazolam can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Midazolam is combined with Stiripentol.
StreptozocinThe serum concentration of Midazolam can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Midazolam is combined with Sufentanil.
SulfinpyrazoneThe serum concentration of Midazolam can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Midazolam can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Midazolam.
SumatriptanThe serum concentration of Midazolam can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Midazolam can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Midazolam is combined with Suvorexant.
TacrineThe serum concentration of Midazolam can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Midazolam can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Midazolam.
TapentadolThe risk or severity of adverse effects can be increased when Midazolam is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Midazolam is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Midazolam.
Taurocholic AcidThe serum concentration of Midazolam can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Midazolam.
TeduglutideThe serum concentration of Midazolam can be increased when it is combined with Teduglutide.
TelaprevirThe serum concentration of Midazolam can be increased when it is combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Midazolam.
TelithromycinThe metabolism of Midazolam can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Midazolam can be increased when it is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Midazolam.
TemocaprilThe serum concentration of Midazolam can be increased when it is combined with Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Midazolam.
TemsirolimusThe serum concentration of Midazolam can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Midazolam can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Midazolam can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Midazolam can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Midazolam can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Midazolam is combined with Tetrodotoxin.
ThalidomideMidazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Midazolam.
TheophyllineThe therapeutic efficacy of Midazolam can be decreased when used in combination with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Midazolam is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Midazolam.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Midazolam.
ThiorphanThe serum concentration of Midazolam can be increased when it is combined with Thiorphan.
ThiotepaThe metabolism of Midazolam can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Midazolam is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Midazolam.
TicagrelorThe serum concentration of Midazolam can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Midazolam can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tiletamine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Midazolam.
TipranavirThe serum concentration of Midazolam can be increased when it is combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tizanidine.
TocilizumabThe serum concentration of Midazolam can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Midazolam is combined with Tolcapone.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Midazolam.
TolvaptanThe serum concentration of Midazolam can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Midazolam is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Midazolam.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Midazolam.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Midazolam.
TrandolaprilThe serum concentration of Midazolam can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Midazolam is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Midazolam is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Midazolam.
TrazodoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Trazodone.
TrazodoneThe serum concentration of Midazolam can be decreased when it is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Triazolam.
TrifluoperazineThe serum concentration of Midazolam can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Midazolam can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Triflupromazine.
TrimethoprimThe serum concentration of Midazolam can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Midazolam can be increased when it is combined with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Midazolam is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Triprolidine.
TroleandomycinThe serum concentration of Midazolam can be increased when it is combined with Troleandomycin.
UbenimexThe serum concentration of Midazolam can be increased when it is combined with Ubenimex.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Midazolam.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Midazolam.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Midazolam.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Midazolam.
VenlafaxineThe metabolism of Midazolam can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Midazolam.
VerapamilThe metabolism of Midazolam can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Midazolam.
VigabatrinThe risk or severity of adverse effects can be increased when Midazolam is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Vilazodone.
VildagliptinThe serum concentration of Midazolam can be increased when it is combined with Vildagliptin.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Midazolam.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Midazolam.
VincristineThe serum concentration of Midazolam can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Midazolam can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Midazolam.
VoriconazoleThe metabolism of Midazolam can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Midazolam is combined with Vortioxetine.
XimelagatranThe serum concentration of Midazolam can be increased when it is combined with Ximelagatran.
XylazineThe risk or severity of adverse effects can be increased when Midazolam is combined with Xylazine.
YohimbineThe therapeutic efficacy of Midazolam can be decreased when used in combination with Yohimbine.
ZaleplonThe risk or severity of adverse effects can be increased when Midazolam is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Midazolam is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Midazolam.
ZimelidineThe risk or severity of adverse effects can be increased when Midazolam is combined with Zimelidine.
ZimelidineThe serum concentration of Midazolam can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Midazolam can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Midazolam is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Midazolam is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Midazolam.
ZonisamideThe risk or severity of adverse effects can be increased when Midazolam is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Midazolam is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Midazolam is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Midazolam is combined with Zuclopenthixol.
Food Interactions
  • Grapefruit juice slows the product's absorption and significantly increases its bioavailability.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transmembrane signaling receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRQ
Uniprot ID:
Q9UN88
Molecular Weight:
72020.875 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Foti RS, Rock DA, Wienkers LC, Wahlstrom JL: Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010 Jun;38(6):981-7. doi: 10.1124/dmd.110.032094. Epub 2010 Mar 4. [PubMed:20203109 ]
  2. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A: Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab. 2004 Oct;5(5):415-42. [PubMed:15544435 ]
  5. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91. [PubMed:12124305 ]
  6. Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002 Dec;30(12):1512-22. [PubMed:12433827 ]
  7. Obach RS, Reed-Hagen AE: Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos. 2002 Jul;30(7):831-7. [PubMed:12065442 ]
  8. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Patki KC, Von Moltke LL, Greenblatt DJ: In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44. [PubMed:12814972 ]
  3. Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, Martin E: Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth. 1994 Nov;73(5):658-61. [PubMed:7826796 ]
  4. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA: Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994 Apr 29;47(9):1643-53. [PubMed:8185679 ]
  3. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D: Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. Drug Metab Dispos. 1996 Sep;24(9):940-7. [PubMed:8886602 ]
  4. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, Wrighton SA: Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther. 1998 Sep;286(3):1253-9. [PubMed:9732386 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP4B1
Uniprot ID:
P13584
Molecular Weight:
58990.64 Da
References
  1. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A4
Uniprot ID:
P22310
Molecular Weight:
60024.535 Da
References
  1. Klieber S, Hugla S, Ngo R, Arabeyre-Fabre C, Meunier V, Sadoun F, Fedeli O, Rival M, Bourrie M, Guillou F, Maurel P, Fabre G: Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Drug Metab Dispos. 2008 May;36(5):851-62. doi: 10.1124/dmd.107.019539. Epub 2008 Feb 6. [PubMed:18256203 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Tassaneeyakul W, Birkett DJ, Miners JO: Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica. 1998 Mar;28(3):293-301. [PubMed:9574817 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764 ]
  2. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13. [PubMed:11231118 ]
  3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  4. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T: Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol. 1998 Oct 9;358(3):289-94. [PubMed:9822896 ]
  5. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372 ]
  6. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  7. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23